Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter

Executive Summary

Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.


Related Content

Flagship Pioneering Nurtures Unique Start-Ups Until They Can Take Wing
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
Google Joins Novartis Backing Medicxi’s New $300m Late-Stage Fund
Pipeline Watch: Phase III Readouts For Guselkumab, Volanesorsen And Dupilumab
Decibel Therapeutics: Protect. Repair. Restore.
Finance Roundup: Tizona, Aspyrian Raise VC Cash; Two Biotechs Ready IPOs
Eyeing The Ear: Start-up Decibel Intends To Tackle Inner-Ear Indications
Trevi Therapeutics Goes Up Against Cara In Itch
INFOGRAPHIC: 72 US IPOs gross $5.7bn in 2014; values rising in 2015
BioNotebook: Trevi, Complexa raise VC cash; Deerfield commits $60m to KemPharm; Aradigm, Voyager deal news; IPO updates


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts